Works matching IS 17762596 AND DT 2025 AND VI 20 AND IP 2
Results: 15
Correction: Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence: Second-Line Chemotherapy for Metastatic Breast Cancer: J. Á. García-Saenz et al.
- Published in:
- 2025
- By:
- Publication type:
- Correction Notice
The Development of ATM Inhibitors in Cancer Therapy: The Development of ATM Inhibitors in Cancer Therapy: E.A. Ampolini et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 2, p. 281, doi. 10.1007/s11523-025-01136-6
- By:
- Publication type:
- Article
Differential Disease Behavior of Immune-Mediated Colitis Among Different Types of Immune Checkpoint Inhibition: Differential IMC Presentation Based on ICI Type: M. Shatila et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 2, p. 339, doi. 10.1007/s11523-025-01135-7
- By:
- Publication type:
- Article
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma: Elranatamab Dosing Regimens to Mitigate CRS: M. Elmeliegy et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 2, p. 349, doi. 10.1007/s11523-025-01134-8
- By:
- Publication type:
- Article
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review: Immunomodulation by Ibrutinib in B Cell Malignancies: D. B. Miklos et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 2, p. 217, doi. 10.1007/s11523-025-01133-9
- By:
- Publication type:
- Article
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions: State of the Art of HER2 Biliary Tract Cancer: S. Camera et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 2, p. 269, doi. 10.1007/s11523-025-01132-w
- By:
- Publication type:
- Article
Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study: Brigatinib for ROS1 NSCLC patients: M. Jean et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 2, p. 311, doi. 10.1007/s11523-025-01131-x
- By:
- Publication type:
- Article
The User's Guide to Amivantamab: The User's Guide to Amivantamab: D. Brazel et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 2, p. 235, doi. 10.1007/s11523-025-01128-6
- By:
- Publication type:
- Article
Checkpoint Inhibition Prior to Stem Cell Transplantation Increases the Risk of Inflammatory Adverse Events: ICI, SCT, and Inflammatory AE: M. Shatila et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 2, p. 329, doi. 10.1007/s11523-025-01127-7
- By:
- Publication type:
- Article
Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study: Immunogenomic Biomarkers of BERIL-1: A. Desilets et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 2, p. 299, doi. 10.1007/s11523-024-01126-0
- By:
- Publication type:
- Article
Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence: Second-Line Chemotherapy for Metastatic Breast Cancer: J. Á. García-Saenz et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 2, p. 191, doi. 10.1007/s11523-024-01125-1
- By:
- Publication type:
- Article
Tumour Mutational Burden and Immune Checkpoint Inhibitor Response in Non-small Cell Lung Cancer: A Continuous Modelling Approach: Continuous Modelling of TMB and ICI Response in NSCLC: M. J. Sorich et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 2, p. 361, doi. 10.1007/s11523-024-01124-2
- By:
- Publication type:
- Article
Bosutinib for the Treatment of CML—Using it Safely: a Podcast: Bosutinib for the Treatment of CML: J. H. Lipton and J. E. Cortes.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 2, p. 183, doi. 10.1007/s11523-024-01123-3
- By:
- Publication type:
- Article
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options: Improved Outcomes in Multiple Myeloma: A Comprehensive Review: S. Mettias et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 2, p. 247, doi. 10.1007/s11523-024-01122-4
- By:
- Publication type:
- Article
Niraparib Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer: Real-World Experience at Hospitals in Spain: Real-World Experience of Niraparib Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer: M. A. Rodríguez Sagrado et al
- Published in:
- Targeted Oncology, 2025, v. 20, n. 2, p. 319, doi. 10.1007/s11523-024-01121-5
- By:
- Publication type:
- Article